T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses
Understanding the immune response to SARS-CoV-2 is dependent on being able to distinguish COVID-19 immune responses from cross-reactive immune responses to other coronaviruses. Here the authors show that choice of antigens and whether an ICS, ELISPOT or T cell proliferation assay is used has a major...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2021-04-01
|
| Series: | Nature Communications |
| Online Access: | https://doi.org/10.1038/s41467-021-21856-3 |
| id |
doaj-316bcccee68f41c8b075256474e98d3e |
|---|---|
| record_format |
Article |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
Ane Ogbe Barbara Kronsteiner Donal T. Skelly Matthew Pace Anthony Brown Emily Adland Kareena Adair Hossain Delowar Akhter Mohammad Ali Serat-E Ali Adrienn Angyal M. Azim Ansari Carolina V. Arancibia-Cárcamo Helen Brown Senthil Chinnakannan Christopher Conlon Catherine de Lara Thushan de Silva Christina Dold Tao Dong Timothy Donnison David Eyre Amy Flaxman Helen Fletcher Joshua Gardner James T. Grist Carl-Philipp Hackstein Kanoot Jaruthamsophon Katie Jeffery Teresa Lambe Lian Lee Wenqin Li Nicholas Lim Philippa C. Matthews Alexander J. Mentzer Shona C. Moore Dean J. Naisbitt Monday Ogese Graham Ogg Peter Openshaw Munir Pirmohamed Andrew J. Pollard Narayan Ramamurthy Patpong Rongkard Sarah Rowland-Jones Oliver Sampson Gavin Screaton Alessandro Sette Lizzie Stafford Craig Thompson Paul J. Thomson Ryan Thwaites Vinicius Vieira Daniela Weiskopf Panagiota Zacharopoulou Oxford Immunology Network Covid-19 Response T Cell Consortium Oxford Protective T Cell Immunology for COVID-19 (OPTIC) Clinical Team Lance Turtle Paul Klenerman Philip Goulder John Frater Eleanor Barnes Susanna Dunachie |
| spellingShingle |
Ane Ogbe Barbara Kronsteiner Donal T. Skelly Matthew Pace Anthony Brown Emily Adland Kareena Adair Hossain Delowar Akhter Mohammad Ali Serat-E Ali Adrienn Angyal M. Azim Ansari Carolina V. Arancibia-Cárcamo Helen Brown Senthil Chinnakannan Christopher Conlon Catherine de Lara Thushan de Silva Christina Dold Tao Dong Timothy Donnison David Eyre Amy Flaxman Helen Fletcher Joshua Gardner James T. Grist Carl-Philipp Hackstein Kanoot Jaruthamsophon Katie Jeffery Teresa Lambe Lian Lee Wenqin Li Nicholas Lim Philippa C. Matthews Alexander J. Mentzer Shona C. Moore Dean J. Naisbitt Monday Ogese Graham Ogg Peter Openshaw Munir Pirmohamed Andrew J. Pollard Narayan Ramamurthy Patpong Rongkard Sarah Rowland-Jones Oliver Sampson Gavin Screaton Alessandro Sette Lizzie Stafford Craig Thompson Paul J. Thomson Ryan Thwaites Vinicius Vieira Daniela Weiskopf Panagiota Zacharopoulou Oxford Immunology Network Covid-19 Response T Cell Consortium Oxford Protective T Cell Immunology for COVID-19 (OPTIC) Clinical Team Lance Turtle Paul Klenerman Philip Goulder John Frater Eleanor Barnes Susanna Dunachie T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses Nature Communications |
| author_facet |
Ane Ogbe Barbara Kronsteiner Donal T. Skelly Matthew Pace Anthony Brown Emily Adland Kareena Adair Hossain Delowar Akhter Mohammad Ali Serat-E Ali Adrienn Angyal M. Azim Ansari Carolina V. Arancibia-Cárcamo Helen Brown Senthil Chinnakannan Christopher Conlon Catherine de Lara Thushan de Silva Christina Dold Tao Dong Timothy Donnison David Eyre Amy Flaxman Helen Fletcher Joshua Gardner James T. Grist Carl-Philipp Hackstein Kanoot Jaruthamsophon Katie Jeffery Teresa Lambe Lian Lee Wenqin Li Nicholas Lim Philippa C. Matthews Alexander J. Mentzer Shona C. Moore Dean J. Naisbitt Monday Ogese Graham Ogg Peter Openshaw Munir Pirmohamed Andrew J. Pollard Narayan Ramamurthy Patpong Rongkard Sarah Rowland-Jones Oliver Sampson Gavin Screaton Alessandro Sette Lizzie Stafford Craig Thompson Paul J. Thomson Ryan Thwaites Vinicius Vieira Daniela Weiskopf Panagiota Zacharopoulou Oxford Immunology Network Covid-19 Response T Cell Consortium Oxford Protective T Cell Immunology for COVID-19 (OPTIC) Clinical Team Lance Turtle Paul Klenerman Philip Goulder John Frater Eleanor Barnes Susanna Dunachie |
| author_sort |
Ane Ogbe |
| title |
T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses |
| title_short |
T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses |
| title_full |
T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses |
| title_fullStr |
T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses |
| title_full_unstemmed |
T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses |
| title_sort |
t cell assays differentiate clinical and subclinical sars-cov-2 infections from cross-reactive antiviral responses |
| publisher |
Nature Publishing Group |
| series |
Nature Communications |
| issn |
2041-1723 |
| publishDate |
2021-04-01 |
| description |
Understanding the immune response to SARS-CoV-2 is dependent on being able to distinguish COVID-19 immune responses from cross-reactive immune responses to other coronaviruses. Here the authors show that choice of antigens and whether an ICS, ELISPOT or T cell proliferation assay is used has a major effect on this discriminatory ability. |
| url |
https://doi.org/10.1038/s41467-021-21856-3 |
| work_keys_str_mv |
AT aneogbe tcellassaysdifferentiateclinicalandsubclinicalsarscov2infectionsfromcrossreactiveantiviralresponses AT barbarakronsteiner tcellassaysdifferentiateclinicalandsubclinicalsarscov2infectionsfromcrossreactiveantiviralresponses AT donaltskelly tcellassaysdifferentiateclinicalandsubclinicalsarscov2infectionsfromcrossreactiveantiviralresponses AT matthewpace tcellassaysdifferentiateclinicalandsubclinicalsarscov2infectionsfromcrossreactiveantiviralresponses AT anthonybrown tcellassaysdifferentiateclinicalandsubclinicalsarscov2infectionsfromcrossreactiveantiviralresponses AT emilyadland tcellassaysdifferentiateclinicalandsubclinicalsarscov2infectionsfromcrossreactiveantiviralresponses AT kareenaadair tcellassaysdifferentiateclinicalandsubclinicalsarscov2infectionsfromcrossreactiveantiviralresponses AT hossaindelowarakhter tcellassaysdifferentiateclinicalandsubclinicalsarscov2infectionsfromcrossreactiveantiviralresponses AT mohammadali tcellassaysdifferentiateclinicalandsubclinicalsarscov2infectionsfromcrossreactiveantiviralresponses AT serateali tcellassaysdifferentiateclinicalandsubclinicalsarscov2infectionsfromcrossreactiveantiviralresponses AT adriennangyal tcellassaysdifferentiateclinicalandsubclinicalsarscov2infectionsfromcrossreactiveantiviralresponses AT mazimansari tcellassaysdifferentiateclinicalandsubclinicalsarscov2infectionsfromcrossreactiveantiviralresponses AT carolinavarancibiacarcamo tcellassaysdifferentiateclinicalandsubclinicalsarscov2infectionsfromcrossreactiveantiviralresponses AT helenbrown tcellassaysdifferentiateclinicalandsubclinicalsarscov2infectionsfromcrossreactiveantiviralresponses AT senthilchinnakannan tcellassaysdifferentiateclinicalandsubclinicalsarscov2infectionsfromcrossreactiveantiviralresponses AT christopherconlon tcellassaysdifferentiateclinicalandsubclinicalsarscov2infectionsfromcrossreactiveantiviralresponses AT catherinedelara tcellassaysdifferentiateclinicalandsubclinicalsarscov2infectionsfromcrossreactiveantiviralresponses AT thushandesilva tcellassaysdifferentiateclinicalandsubclinicalsarscov2infectionsfromcrossreactiveantiviralresponses AT christinadold tcellassaysdifferentiateclinicalandsubclinicalsarscov2infectionsfromcrossreactiveantiviralresponses AT taodong tcellassaysdifferentiateclinicalandsubclinicalsarscov2infectionsfromcrossreactiveantiviralresponses AT timothydonnison tcellassaysdifferentiateclinicalandsubclinicalsarscov2infectionsfromcrossreactiveantiviralresponses AT davideyre tcellassaysdifferentiateclinicalandsubclinicalsarscov2infectionsfromcrossreactiveantiviralresponses AT amyflaxman tcellassaysdifferentiateclinicalandsubclinicalsarscov2infectionsfromcrossreactiveantiviralresponses AT helenfletcher tcellassaysdifferentiateclinicalandsubclinicalsarscov2infectionsfromcrossreactiveantiviralresponses AT joshuagardner tcellassaysdifferentiateclinicalandsubclinicalsarscov2infectionsfromcrossreactiveantiviralresponses AT jamestgrist tcellassaysdifferentiateclinicalandsubclinicalsarscov2infectionsfromcrossreactiveantiviralresponses AT carlphilipphackstein tcellassaysdifferentiateclinicalandsubclinicalsarscov2infectionsfromcrossreactiveantiviralresponses AT kanootjaruthamsophon tcellassaysdifferentiateclinicalandsubclinicalsarscov2infectionsfromcrossreactiveantiviralresponses AT katiejeffery tcellassaysdifferentiateclinicalandsubclinicalsarscov2infectionsfromcrossreactiveantiviralresponses AT teresalambe tcellassaysdifferentiateclinicalandsubclinicalsarscov2infectionsfromcrossreactiveantiviralresponses AT lianlee tcellassaysdifferentiateclinicalandsubclinicalsarscov2infectionsfromcrossreactiveantiviralresponses AT wenqinli tcellassaysdifferentiateclinicalandsubclinicalsarscov2infectionsfromcrossreactiveantiviralresponses AT nicholaslim tcellassaysdifferentiateclinicalandsubclinicalsarscov2infectionsfromcrossreactiveantiviralresponses AT philippacmatthews tcellassaysdifferentiateclinicalandsubclinicalsarscov2infectionsfromcrossreactiveantiviralresponses AT alexanderjmentzer tcellassaysdifferentiateclinicalandsubclinicalsarscov2infectionsfromcrossreactiveantiviralresponses AT shonacmoore tcellassaysdifferentiateclinicalandsubclinicalsarscov2infectionsfromcrossreactiveantiviralresponses AT deanjnaisbitt tcellassaysdifferentiateclinicalandsubclinicalsarscov2infectionsfromcrossreactiveantiviralresponses AT mondayogese tcellassaysdifferentiateclinicalandsubclinicalsarscov2infectionsfromcrossreactiveantiviralresponses AT grahamogg tcellassaysdifferentiateclinicalandsubclinicalsarscov2infectionsfromcrossreactiveantiviralresponses AT peteropenshaw tcellassaysdifferentiateclinicalandsubclinicalsarscov2infectionsfromcrossreactiveantiviralresponses AT munirpirmohamed tcellassaysdifferentiateclinicalandsubclinicalsarscov2infectionsfromcrossreactiveantiviralresponses AT andrewjpollard tcellassaysdifferentiateclinicalandsubclinicalsarscov2infectionsfromcrossreactiveantiviralresponses AT narayanramamurthy tcellassaysdifferentiateclinicalandsubclinicalsarscov2infectionsfromcrossreactiveantiviralresponses AT patpongrongkard tcellassaysdifferentiateclinicalandsubclinicalsarscov2infectionsfromcrossreactiveantiviralresponses AT sarahrowlandjones tcellassaysdifferentiateclinicalandsubclinicalsarscov2infectionsfromcrossreactiveantiviralresponses AT oliversampson tcellassaysdifferentiateclinicalandsubclinicalsarscov2infectionsfromcrossreactiveantiviralresponses AT gavinscreaton tcellassaysdifferentiateclinicalandsubclinicalsarscov2infectionsfromcrossreactiveantiviralresponses AT alessandrosette tcellassaysdifferentiateclinicalandsubclinicalsarscov2infectionsfromcrossreactiveantiviralresponses AT lizziestafford tcellassaysdifferentiateclinicalandsubclinicalsarscov2infectionsfromcrossreactiveantiviralresponses AT craigthompson tcellassaysdifferentiateclinicalandsubclinicalsarscov2infectionsfromcrossreactiveantiviralresponses AT pauljthomson tcellassaysdifferentiateclinicalandsubclinicalsarscov2infectionsfromcrossreactiveantiviralresponses AT ryanthwaites tcellassaysdifferentiateclinicalandsubclinicalsarscov2infectionsfromcrossreactiveantiviralresponses AT viniciusvieira tcellassaysdifferentiateclinicalandsubclinicalsarscov2infectionsfromcrossreactiveantiviralresponses AT danielaweiskopf tcellassaysdifferentiateclinicalandsubclinicalsarscov2infectionsfromcrossreactiveantiviralresponses AT panagiotazacharopoulou tcellassaysdifferentiateclinicalandsubclinicalsarscov2infectionsfromcrossreactiveantiviralresponses AT oxfordimmunologynetworkcovid19responsetcellconsortium tcellassaysdifferentiateclinicalandsubclinicalsarscov2infectionsfromcrossreactiveantiviralresponses AT oxfordprotectivetcellimmunologyforcovid19opticclinicalteam tcellassaysdifferentiateclinicalandsubclinicalsarscov2infectionsfromcrossreactiveantiviralresponses AT lanceturtle tcellassaysdifferentiateclinicalandsubclinicalsarscov2infectionsfromcrossreactiveantiviralresponses AT paulklenerman tcellassaysdifferentiateclinicalandsubclinicalsarscov2infectionsfromcrossreactiveantiviralresponses AT philipgoulder tcellassaysdifferentiateclinicalandsubclinicalsarscov2infectionsfromcrossreactiveantiviralresponses AT johnfrater tcellassaysdifferentiateclinicalandsubclinicalsarscov2infectionsfromcrossreactiveantiviralresponses AT eleanorbarnes tcellassaysdifferentiateclinicalandsubclinicalsarscov2infectionsfromcrossreactiveantiviralresponses AT susannadunachie tcellassaysdifferentiateclinicalandsubclinicalsarscov2infectionsfromcrossreactiveantiviralresponses |
| _version_ |
1721531245239730176 |
| spelling |
doaj-316bcccee68f41c8b075256474e98d3e2021-04-11T11:12:20ZengNature Publishing GroupNature Communications2041-17232021-04-0112111410.1038/s41467-021-21856-3T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responsesAne Ogbe0Barbara Kronsteiner1Donal T. Skelly2Matthew Pace3Anthony Brown4Emily Adland5Kareena Adair6Hossain Delowar Akhter7Mohammad Ali8Serat-E Ali9Adrienn Angyal10M. Azim Ansari11Carolina V. Arancibia-Cárcamo12Helen Brown13Senthil Chinnakannan14Christopher Conlon15Catherine de Lara16Thushan de Silva17Christina Dold18Tao Dong19Timothy Donnison20David Eyre21Amy Flaxman22Helen Fletcher23Joshua Gardner24James T. Grist25Carl-Philipp Hackstein26Kanoot Jaruthamsophon27Katie Jeffery28Teresa Lambe29Lian Lee30Wenqin Li31Nicholas Lim32Philippa C. Matthews33Alexander J. Mentzer34Shona C. Moore35Dean J. Naisbitt36Monday Ogese37Graham Ogg38Peter Openshaw39Munir Pirmohamed40Andrew J. Pollard41Narayan Ramamurthy42Patpong Rongkard43Sarah Rowland-Jones44Oliver Sampson45Gavin Screaton46Alessandro Sette47Lizzie Stafford48Craig Thompson49Paul J. Thomson50Ryan Thwaites51Vinicius Vieira52Daniela Weiskopf53Panagiota Zacharopoulou54Oxford Immunology Network Covid-19 Response T Cell ConsortiumOxford Protective T Cell Immunology for COVID-19 (OPTIC) Clinical TeamLance Turtle55Paul Klenerman56Philip Goulder57John Frater58Eleanor Barnes59Susanna Dunachie60Nuffield Department of Clinical Medicine, Peter Medawar Building for Pathogen Research, University of OxfordNuffield Department of Clinical Medicine, Peter Medawar Building for Pathogen Research, University of OxfordNuffield Department of Clinical Medicine, Peter Medawar Building for Pathogen Research, University of OxfordNuffield Department of Clinical Medicine, Peter Medawar Building for Pathogen Research, University of OxfordNuffield Department of Clinical Medicine, Peter Medawar Building for Pathogen Research, University of OxfordNuffield Department of Clinical Medicine, Peter Medawar Building for Pathogen Research, University of OxfordDepartment of Molecular and Clinical Pharmacology, MRC Centre for Drug Safety Science, University of LiverpoolNuffield Department of Clinical Medicine, Peter Medawar Building for Pathogen Research, University of OxfordNuffield Department of Clinical Medicine, Peter Medawar Building for Pathogen Research, University of OxfordDepartment of Molecular and Clinical Pharmacology, MRC Centre for Drug Safety Science, University of LiverpoolThe Florey Institute for Host-Pathogen Interactions and Department of Infection, Immunity and Cardiovascular Disease, Medical School, University of SheffieldNuffield Department of Clinical Medicine, Peter Medawar Building for Pathogen Research, University of OxfordNuffield Department of Clinical Neurosciences, University of OxfordNuffield Department of Clinical Medicine, Peter Medawar Building for Pathogen Research, University of OxfordNuffield Department of Clinical Medicine, Peter Medawar Building for Pathogen Research, University of OxfordNuffield Department of Clinical Medicine, Centre for Tropical Medicine and Global Health, University of OxfordNuffield Department of Clinical Medicine, Peter Medawar Building for Pathogen Research, University of OxfordThe Florey Institute for Host-Pathogen Interactions and Department of Infection, Immunity and Cardiovascular Disease, Medical School, University of SheffieldOxford Vaccine Group, Department of Paediatrics, University of OxfordMRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, University of OxfordNuffield Department of Clinical Medicine, Peter Medawar Building for Pathogen Research, University of OxfordOxford University Hospitals NHS Foundation TrustJenner Institute, University of OxfordDepartment of Infection Biology, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical MedicineDepartment of Molecular and Clinical Pharmacology, MRC Centre for Drug Safety Science, University of LiverpoolNIHR Oxford Biomedical Research Centre, University of OxfordNuffield Department of Clinical Medicine, Peter Medawar Building for Pathogen Research, University of OxfordDepartment of Molecular and Clinical Pharmacology, MRC Centre for Drug Safety Science, University of LiverpoolOxford University Hospitals NHS Foundation TrustJenner Institute, University of OxfordNuffield Department of Clinical Medicine, Peter Medawar Building for Pathogen Research, University of OxfordNuffield Department of Clinical Medicine, Peter Medawar Building for Pathogen Research, University of OxfordNuffield Department of Clinical Medicine, Peter Medawar Building for Pathogen Research, University of OxfordNuffield Department of Clinical Medicine, Peter Medawar Building for Pathogen Research, University of OxfordOxford University Hospitals NHS Foundation TrustHPRU in Emerging and Zoonotic Infections, Institute of Infection, Veterinary and Ecological Sciences, University of LiverpoolDepartment of Molecular and Clinical Pharmacology, MRC Centre for Drug Safety Science, University of LiverpoolDepartment of Molecular and Clinical Pharmacology, MRC Centre for Drug Safety Science, University of LiverpoolOxford University Hospitals NHS Foundation TrustFaculty of Medicine, National Heart and Lung institute, Imperial CollegeDepartment of Molecular and Clinical Pharmacology, MRC Centre for Drug Safety Science, University of LiverpoolOxford Vaccine Group, Department of Paediatrics, University of OxfordNuffield Department of Clinical Medicine, Peter Medawar Building for Pathogen Research, University of OxfordNuffield Department of Clinical Medicine, Peter Medawar Building for Pathogen Research, University of OxfordThe Florey Institute for Host-Pathogen Interactions and Department of Infection, Immunity and Cardiovascular Disease, Medical School, University of SheffieldNuffield Department of Clinical Medicine, Peter Medawar Building for Pathogen Research, University of OxfordWellcome Centre for Human Genetics, University of OxfordCenter for Infectious Disease and Vaccine Research, La Jolla Institute for ImmunologyOxford University Hospitals NHS Foundation TrustPeter Medawar Building for Pathogen Research, Department of Zoology, University of OxfordDepartment of Molecular and Clinical Pharmacology, MRC Centre for Drug Safety Science, University of LiverpoolFaculty of Medicine, National Heart and Lung institute, Imperial CollegeNuffield Department of Clinical Medicine, Peter Medawar Building for Pathogen Research, University of OxfordCenter for Infectious Disease and Vaccine Research, La Jolla Institute for ImmunologyNuffield Department of Clinical Medicine, Peter Medawar Building for Pathogen Research, University of OxfordHPRU in Emerging and Zoonotic Infections, Institute of Infection, Veterinary and Ecological Sciences, University of LiverpoolNuffield Department of Clinical Medicine, Peter Medawar Building for Pathogen Research, University of OxfordPeter Medawar Building for Pathogen Research, Department of Paediatrics, University of OxfordNuffield Department of Clinical Medicine, Peter Medawar Building for Pathogen Research, University of OxfordNuffield Department of Clinical Medicine, Peter Medawar Building for Pathogen Research, University of OxfordNuffield Department of Clinical Medicine, Peter Medawar Building for Pathogen Research, University of OxfordUnderstanding the immune response to SARS-CoV-2 is dependent on being able to distinguish COVID-19 immune responses from cross-reactive immune responses to other coronaviruses. Here the authors show that choice of antigens and whether an ICS, ELISPOT or T cell proliferation assay is used has a major effect on this discriminatory ability.https://doi.org/10.1038/s41467-021-21856-3 |